Filtration markers and determination methods for the assessment of kidney function

Noninvasive Diagnosis of Early-Stage Chronic Kidney Disease and Monitoring of the Hemodialysis Process in Clinical Practice via Exhaled Breath Analysis Using an Ultrasensitive Flexible NH3 Sensor Assisted by Pattern Recognition

To achieve the early diagnosis of chronic kidney disease (CKD), noninvasive hemodialysis monitoring, and accurate determination of dialysis duration and adequacy, a noninvasive, point-of-care, user-friendly device should be developed. Here, a flexible, room temperature NH3 gas sensor sensitive to the key breath biomarkers of CKD─NH3 and creatinine─was fabricated. The sensor had detection limits of 100 ppb for NH3 and 1 ppm for creatinine. Clinically, a total of 96 exhaled breath samples, half from 39 CKD patients and the other half from 48 healthy controls were collected and analyzed. With the assistance of a pattern recognition algorithm , the early diagnosis of CKD was achieved by the sensor, with PCA being used due to sensor's cross-sensitivity to CKD biomarkers. Diagnostic models distinguishing CKD versus non-CKD and early-stage CKD versus advanced-stage CKD were constructed using the SVM algorithm, achieving an overall accuracy of 0.93 and 0.94, with area under the curve (AUC) values of 0.97 and 0.99 for all subjects in receiver operating characteristic (ROC) analysis, respectively. The hemodialysis processes of patients were monitored in real-time, with the sensor response values exhibiting ideal exponential decay over time. The sensor response values showed a strong positive correlation with serum creatinine levels (r = 0.85) and a moderate positive correlation with blood urea nitrogen levels (r = 0.62), both of which are key clinical diagnostic indicators for CKD. These are good results, as 54% of CKD samples are from early-stage CKD patients. These results suggest that the sensor could serve as a noninvasive alternative to traditional blood tests for renal function evaluation and CKD diagnosis. Overall, this sensor demonstrates great potential in clinical practice for early diagnosis of CKD, monitoring the daily health status of CKD patients, optimizing the dialysis schedule, and monitoring the dialysis process in real-time.

Accuracy of estimating equations for the assessment of glomerular filtration rate in critically ill patients versus outpatients

BACKGROUND

Estimating equations for the assessment of glomerular filtration rate (GFR) have been poorly investigated in the critical care setting. We evaluated the agreement between the GFR measured with 51CrEDTA/iohexol (mGFR) and four estimating equations based on serum concentrations of creatine and/or cystatin C (eGFR) in two cohorts: critically ill patients and outpatients with normal-to-moderately reduced GFR.

METHODS

Forty-three patients in the critical care group and 48 patients in the outpatient group were included. GFR was measured (mGFR) by plasma infusion clearance of 51Cr-EDTA/iohexol (critical care group) and the single injection, one-sample plasma 51Cr-EDTA clearance technique (outpatients). The following estimating equations (eGFR) were used: the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for creatinine (CKD-EPICr), cystatin C (CKD-EPICys C), creatinine+cystatin C (CKD-EPICr + Cys C) and the Lund-Malmö creatinine+cystatin C equation (LMCr + Cys C). Agreement between mGFR and eGFR was assessed by the Bland-Altman method and accuracy by calculating P30 and P10.

RESULTS

In the critically ill group, the bias between the estimating equations and mGFR was -3.6 to 2.8 mL/min/1.73 m2, while the error was 121%-127% and the accuracy (P30) 33%-40%. In the outpatients, the bias between the estimating equations and mGFR was -13.0 to 7.6 mL/min/1.73 m2, while the error was 31%-41% and the accuracy (P30), 67%-96%.

CONCLUSIONS

All four equations performed poorly in assessing GFR in the critically ill cohort with an unacceptably high error and low accuracy in contrast to the outpatient group. To accurately assess GFR in critically ill patients, GFR must be measured not estimated.

EDITORIAL COMMENT

For the assessment of glomerular filtration rate (GFR), it can be measured directly, but is frequently estimated using a point measure of serum creatinine concentration. In this study, ICU case GFR estimations, by different adjusted equations, done also for a cohort of outpatients, showed that these serum creatinine-based estimations for ICU cases are not highly precise or reliable.

iPSCs as a groundbreaking tool for the study of adverse drug reactions: A new avenue for personalized therapy

Induced pluripotent stem cells (iPSCs), obtained by reprogramming different somatic cell types, represent a promising tool for the study of drug toxicities, especially in the context of personalized medicine. Indeed, these cells retain the same genetic heritage of the donor, allowing the development of personalized models. In addition, they represent a useful tool for the study of adverse drug reactions (ADRs) in special populations, such as pediatric patients, which are often poorly represented in clinical trials due to ethical issues. Particularly, iPSCs can be differentiated into any tissue of the human body, following several protocols which use different stimuli to induce specific differentiation processes. Differentiated cells also maintain the genetic heritage of the donor, and therefore are suitable for personalized pharmacological studies; moreover, iPSC-derived differentiated cells are a valuable tool for the investigation of the mechanisms underlying the physiological differentiation processes. iPSCs-derived organoids represent another important tool for the study of ADRs. Precisely, organoids are in vitro 3D models which better represent the native organ, both from a structural and a functional point of view. Moreover, in the same way as iPSC-derived 2D models, iPSC-derived organoids are appropriate personalized models since they retain the genetic heritage of the donor. In comparison to other in vitro models, iPSC-derived organoids present advantages in terms of versatility, patient-specificity, and ethical issues. This review aims to provide an updated report of the employment of iPSCs, and 2D and 3D models derived from these, for the study of ADRs. This article is categorized under: Cancer > Stem Cells and Development.

Removal of ethnicity adjustment for creatinine-based estimated glomerular filtration rate equations

Creatinine-based estimated glomerular filtration rate equations (eGFRcreatinine) are used to measure excretory kidney function in clinical practice. Despite inter and intra-patient variability, eGFRcreatinine has excellent clinical utility and provides the basis for the classification system for chronic kidney disease (CKD), for kidney function monitoring, treatment interventions and referral pathways. The 4-variable modification of diet in renal disease (MDRD) eGFRcreatinine equation was introduced in 2000 and recommended by the National Institute for Health and Care Excellence (NICE) in 2008. Subsequently, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFRcreatinine equation was introduced in 2009 and is more accurate than MDRD in patients with mild and moderate CKD. In 2014, NICE recommended that CKD-EPI eGFRcreatinine replace MDRD eGFRcreatinine in routine clinical practice across England. Both equations originally incorporated adjustments for age, gender and ethnicity. However, the evidence for ethnicity adjustment has been increasingly questioned, and in 2021 NICE recommended that kidney function should be estimated by CKD-EPI eGFRcreatinine without using ethnicity adjustment. Recently, a CKD-EPI equation has been presented without ethnicity adjustment; however, this has not been validated outside of North America and NICE continues to recommend CKD-EPI 2009. We review the status of eGFRcreatinine in clinical practice, including the limitations of eGFRcreatinine and the rationale for removal of ethnicity adjustment and the potential impact of this change on clinical care for patients with kidney disease.

Effects of Glycyrrhiza Glabra (Licorice) Root Extract on the Hormones, Serum Biochemicals, and Hematological Parameters in Dogs with Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is the most common prostate disorder in non-neutered dogs and is often caused by androgenic stimulation or changes in the ratio of androgen to estrogen. Also, it is commonly seen in neutered older dogs. Clinical signs may not be presented, but persistent or intermittent hematuria, hemospermia, or a primary hemorrhagic discharge are usually reported. In this research, ethanolic extract of licorice root (EELR) was used as the treatment, which has various antioxidant and healing properties and can reduce lesions by establishing an antioxidant balance and reducing inflammation. For this experiment, 30 dogs of approximately the same age and weight were randomly divided into 6 groups of 5 each. The treatment groups received the EELR at doses of 10 and 20 mg/kg separately, while the control group received no medications. At the end of the 9-week treatment period, biochemical and hormonal factors were measured and analyzed by blood sampling. The results showed that the EELR has multiple positive effects on the serum biochemical indices and also positively affects hormone levels, while it can decrease the prostate-specific antigen (PSA) level in BPH dogs. In conclusion, the EELR can effectively reduce BPH-induced lesions without any side effects.

Molecular Visualization of Early-Stage Acute Kidney Injury with a DNA Framework Nanodevice

DNA nanomachines with artificial intelligence have attracted great interest, which may open a new era of precision medicine. However, their in vivo behavior, including early diagnosis and therapeutic effect are limited by their targeting efficiency. Here, a tetrahedral DNA framework (TDF)-based nanodevice for in vivo near-infrared (NIR) diagnosis of early-stage AKI is developed. This nanodevice comprises three functional modules: a size-tunable TDF nanostructure as kidney-targeting vehicle, a binding module for the biomarker kidney injury molecule-1 (Kim-1), and a NIR signaling module. The cooperation of these modules allows the nanodevice to be selectively accumulated in injured kidney tissues with high Kim-1 level, generating strong NIR fluorescence; whereas the nanodevice with the proper size can be rapidly cleared in healthy kidneys to minimize the background. By using this nanodevice, the early diagnosis of AKI onset is demonstrated at least 6 h ahead of Kim-1 urinalysis, or 12 h ahead of blood detection. It is envisioned that this TDF-based nanodevice may have implications for the early diagnosis of AKI and other kidney diseases.

Near-infrared fluorescent molecular probes for imaging and diagnosis of nephro-urological diseases

Near-infrared (NIR) fluorescence imaging has improved imaging depth relative to conventional fluorescence imaging in the visible region, demonstrating great potential in both fundamental biomedical research and clinical practice. To improve the detection specificity, NIR fluorescence imaging probes have been under extensive development. This review summarizes the particular application of optical imaging probes with the NIR-I window (700-900 nm) or the NIR-II window (1000-1700 nm) emission for diagnosis of nephron-urological diseases. These molecular probes have enabled contrast-enhanced imaging of anatomical structures and physiological function as well as molecular imaging and early diagnosis of acute kidney injury, iatrogenic ureteral injury and bladder cancer. The design strategies of molecular probes are specifically elaborated along with representative imaging applications. The potential challenges and perspectives in this field are also discussed.

Transcutaneous Measurement of Glomerular Filtration Rate in Rodents

Glomerular filtration rate (GFR) is considered the gold standard to test kidney function. However, the serial blood and/or urine sample collection required for the calculation of the GFR is stressful for the animal and time consuming for the experimenter. Here, we describe a transcutaneous assessment of renal function in conscious animals that does not require plasma or urine sampling and/or deep anesthesia. For the measurement, we use a near-infrared (NIR) device that records the excretion kinetic of the renal marker ABZWCY-HPβCD. ABZWCY-HPβCD is a new hydrophilic, stable, and nontoxic NIR fluorescent agent that can be used as a renal marker as it is filtrated and completely excreted through the kidneys into the urine without reabsorption or secretion and without accumulation in the skin. The data recorded in the device are then analyzed with "GFRmeasure," an open-source, freely downloadable, and user-friendly software.

Renal-clearable Molecular Semiconductor for Second Near-Infrared Fluorescence Imaging of Kidney Dysfunction

Real-time imaging of kidney function is important to assess the nephrotoxicity of drugs and monitor the progression of renal diseases; however, it remains challenging because of the lack of optical agents with high renal clearance and high signal-to-background ratio (SBR). Herein, a second near-infrared (NIR-II) fluorescent molecular semiconductor (CDIR2) is synthesized for real-time imaging of kidney dysfunction in living mice. CDIR2 not only has a high renal clearance efficiency (≈90 % injection dosage at 24 h post-injection), but also solely undergoes glomerular filtration into urine without being reabsorbed and secreted in renal tubules. Such a unidirectional renal clearance pathway of CDIR2 permits real-time monitoring of kidney dysfunction in living mice upon nephrotoxic exposure. Thus, this study not only introduces a molecular renal probe but also provides useful molecular guidelines to increase the renal clearance efficiency of NIR-II fluorescent agents.

The therapeutic potential of targeting the Kir1.1 (renal outer medullary K+) channel

K_ir1.1 (renal outer medullary K⁺) channels are potassium channels expressed almost exclusively in the kidney and play a role in the body's electrolyte and water balance. Potassium efflux through K_ir1.1 compliments the role of transporters and sodium channels that are the targets of known diuretics. Consequently, loss-of-function mutations in men and rodents are associated with salt wasting and low blood pressure. On this basis, K_ir1.1 inhibitors may have value in the treatment of hypertension and heart failure. Efforts to develop small molecule K_ir1.1 inhibitors produced MK-7145, which entered into clinical trials. The present manuscript describes the structure-activity relationships associated with this scaffold alongside other preclinical K_ir1.1 blockers.

Light-Emitting Agents for Noninvasive Assessment of Kidney Function

The noninvasive assessment of kidney function and diagnosis of kidney disease have long been challenges. Traditional methods are not routinely available, because the existing protocols are cumbersome, time consuming, and invasive. In the past few years, significant progress in the area of diagnosing kidney function and disease on the basis of light-emitting agents has been made. Herein, we briefly review light-emitting agents, including organic fluorescent agents and inorganic renal clearable luminescent nanoparticles for the noninvasive and real-time monitoring of kidney function and disease. Moreover, some significant requirements and strategies regarding the design of ideal glomerular filtration rate agents and renal clearable nanoparticles are discussed. Finally, we discuss future challenges in expediting clinical translation of these developed light-emitting agents, along with considerations of the efforts that need to be made to develop new agents and diagnosing kidney disease.

Zwitterionic near infrared fluorescent agents for noninvasive real-time transcutaneous assessment of kidney function

Zwitterionic near infrared fluorescent agents were developed for non-invasive real-time transcutaneous assessment of kidney function.

We developed novel zwitterionic near infrared (NIR) fluorescent agents (ABZWCY-HPβCD and AAZWCY-HPβCD), which exhibit favorable hydrophilicity, low plasma protein binding, high stability and non-toxicity. These attractive characteristics ensure that they are excreted rapidly, without any skin accumulation or metabolism in vivo. More importantly, zwitterionic HPβCD based agents can be efficiently filtrated by the glomerulus and completely excreted through the kidneys into urine without reabsorption or secretion in the kidney proximal tubule. Relying on these novel zwitterionic NIR agents and a transcutaneous device, we demonstrate a rapid, robust and biocompatible approach for assessing kidney function in rat models of both healthy rats and those with kidney disease, without the need for time-consuming blood/urine sample preparation. Our work provides a promising tool for in vivo real-time non-invasive kidney function assessment in preclinical applications.